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Abstract
Background: Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most
common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a
therapeutic effect in vitro and in vivo models.
Method: We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we
used and animal model to determined, PCNA and MAT1A expression and transaminases levels.
Results: We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was
82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib
group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D
62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and
GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L).
Conclusion: The combination of pravastatin + sorafenib were more effective than Sorafenib alone.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy worldwide. It ranks third place in the list
of malignancies leading to death [1] and the incidence of
HCC has increased in eastern Asia, Europe and the United
States [2]. Clinically, HCC is characterized by its invasive-
ness, poor prognosis and limited therapeutic opportu-
nities. In many patients, HCC is diagnosed at an advanced
stage. For these patients, the US Food and Drug Adminis-
tration has approved the multikinase inhibitor, sorafenib
[3,4]. In recent years, two studies have been published
[5,6] which demonstrate that pravastatin increases the sur-
vival of patients with advanced hepatocellular cancer alone
or in combination with chemoembolization.
The molecular pathogenesis of HCC is complex and
involves the abnormal clonal expansion of dysplastic
hepatocytes, anti-apoptotic signalling and the stimula-
tion of angiogenesis-associated growth factors [7].
Today, statins are regarded as attractive molecules and
they may affect cancer. Statins, the 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors,
are a class of drugs that inhibit the rate-limiting step in
the cholesterol biosynthesis pathway, cholesterol being
an important structural component of cell membranes.
Various studies have been reported describing an asso-
ciation of statins with either an increase or a decrease in
the incidence of various cancers [8,9]. On the other
hand, drug resistance is the major problem of che-
motherapy, which causes treatment failure leading to
progressive disease. Potential mechanisms of resistance
include activation of the Ras/Raf/MEK/ERK signal trans-
duction cascade [10] but also increased cholesterol levels
in cancer cells [11].
One of the potential mechanisms of action of statins is
the modulation of the cell cycle through the down-regula-
tion of cell cycle promoters such as cyclin D1-dependant
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any medium, provided the original work is properly cited.kinase (CdK) and the up-regulation of cell cycle inhibitors
p21 and p27 [12-15]. It has also been observed that they
favour the regulation of homeostasis of the liver by
increasing the expression of methionine adenosyltransfer-
ase (MAT-1) and decrease cell proliferation by reducing
the levels of the Proliferating Cell Nuclear Antigen
(PCNA) [16-18]. They also inhibit the activity of matrix
metalloproteinases (MMPs), especially of MMP-2 and
MMP-9. Further, it has been reported that statins decrease
the activity of MMP-9 by 75% [15]. This activity is directly
related to tumour invasion and metastasis.
Materials and methods
Cell line and culture
The human hepatoma PLC cells were obtained from the
ATCC. PLCs were cultured in Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM) supplemented with 10% foetal
bovine serum, penicillin G (100 U/ml) and streptomycin
(100 μg/ml).
Cell proliferation
Proliferation in cell culture was measured using the Cell-
Titer 96 AQueous Non-radioactive cell proliferation assay
(Promega, Spain). PLC cells were seeded onto 96-well
plates, 10,000 cells/ml, and treated for 4 h. Following each
treatment, 20 μl of dye solution was added to each well
and incubated for 4 h. Subsequently, the absorbance was
recorded at 490 nm using an ELISA plate reader. The pra-
vastatin and sorafenib were used at concentrations of
50 μM.
Animal experiments
All animal studies were performed in accordance with
and approved by the Institutional Animal Care and Use
Committee. We used Wistar male rats (Charles River,
Spain) with initial body weights between 225 and 250 g.
To develop a rat model of HCC, we used diethylnitrosa-
mine (DEN). This was administered by orogastric catheter,
three times a week for 19 weeks. All these animals devel-
oped HCC. The rats were divided into five groups with
three experimental groups, corresponding to different
drug regimens (Figure 1):
1. CONTROL (C) Group (N = 10): free access to food
and water for 19 weeks
2. HCC (D) Group (N = 10): Idem control group but
this group were administered DEN three times a week.
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Figure 1 Animal model.
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Page 2 of 73. PRAVASTATIN (P) Group (N = 10): Idem HCC
group, with the addition of a dose of 0.6 mg/kg/d of
pravastatin given daily by orogastric catheter for 19
weeks.
4. SORAFENIB (S) Group (N = 10): Idem HCC group,
with the addition of a dose of 11.4 mg/kg/d of sorafenib
daily by orogastric catheter.
5. SORAFENIB + PRAVASTATIN (P + S) Group
(N = 10): Idem HCC group, with the addition of a com-
b i n e dd o s eo f0 . 6m g / k g / do fp r a v a s t a t i na n d1 1 . 4m g /
kg/d of sorafenib, administered as for P and S Groups.
Histology
After sacrificing the animal, the liver was sectioned to
allow macroscopic assessment of the hepatic lesions. In
addition, several portions (1 cm
3)o ft h el i v e rw e r e
removed and fixed in 10% formaldehyde for 24 h. Sub-
sequently, this tissue was processed: it was embedded in
p a r a f f i na n d3a n d5μm sections taken (Microtome,
Leitz) which were fixed on slides and stained with hae-
matoxylin and eosin. Samples were then mounted and
examined under an optical microscope to characterise
the lesions.
Determination of PCNA and MAT1A
The expression of PCNA (Cayman Chemical, Madrid) and
MAT1A (bioNova científica, Madrid) in the liver tissue
was measured using specific antibodies. For this, different
tissue biopsies (1 cm
3) were taken, fixed in 40 g/l of for-
maldehyde buffer, embedded in paraffin and cut into 4 μm
sections. Paraffin was removed with xylene, and samples
were dehydrated with alcohol and subsequently used for
immunohistochemical analysis. The Dako EnVision Sys-
tem-HRP (DAB) was used for immunohistochemical
staining, while quantification was carried out using the
Genetix Ariol SL-50 system.
Statistical analysis
The Chi Square test was used to determine the exis-
tence of differences in the qualitative variables between
the groups, while for quantitative variables ANOVA and
Kruskal-Wallis tests were applied depending on the dis-
tribution of variables. Multiple comparisons were carried
out using the Tukey and Scheffé tests and/or the Mann
Whitney test. A level of significance of p < 0.05 was
selected.
Results
Pravastatin inhibis proliferation in PLC cells
We observed that cell proliferation was considerably
lower in all the three experimental groups with the
reduction being the most clear in the group adminis-
tered pravastatin and sorafenib (P 82% (Abs 0.82), S
51% Abs (0.51), P + S 40% (Abs 0.4) compared to the
untreated cells; p < 0.05) (Figure 2).
It was found that all the rats treated with DEN
showed advanced HCC at both macro and microscopic
levels. In rats treated with pravastatin, sorafenib or a
combination thereof, the size of the tumours was signifi-
cantly smaller and, at the microscopic level, the rats
treated with pravastatin and pravastatin + sorafenib con-
tained a smaller number of tumour cells (p < 0.05) while
the sorafenib group had dysplastic nodules (Figure 3).
In the immunohistochemistry images, we note that the
DEN group can be seen to have significantly higher
PCNA levels than the other groups (Figure 4A). In the
combined P + S Group levels were less elevated than in
the other experimental groups (D 91.42%, P 80%, S
76.41%, P + S 72.72%) (Figure 4B)(p < 0.001).
The immunohistochemistry analysis revealed that the
level of MAT1A was notably lower in the DEN group,
while in the other groups it was significantly higher (p <
0.05) (Figure 5A). This difference was much more signif-
icant in the groups given pravastatin than in the other
animals (D 62%, P 94%, S 71%, P + S 91%) (p < 0.05)
(Figure 5B).
Pravastatin, sorafenib and the combination of thereof
decrease the levels of transaminases
We also observed significantly lower levels of GOT,
GPT, GGT and alkaline phosphatise (ALP) in the three
experimental groups. Moreover, this decrease was more
significant in the pravastatin groups (D 619.5 U/L; 271
U/L; 58.35 U/L; 190 U/L) (P 117.5 U/L;43.5 U/L;7 U/
L;129 U/L) (S 147 U/L;59 U/L;23 U/L;172 U/L) (P + S
142 U/L;59.5 U/L;7 U/L;137 U/L) (p < 0.05) (Figure 6).
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Figure 2 Levels of proliferation in PLC cells.
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In spite of the promising results in the treatment of HCC,
it still is a disease with poor prognosis, therefore it is
necessary to search for new drugs. Moreover, the use of
chemotherapy in patients suffering from chronic liver
disease is associated with a high rate of severe adverse
effects and even death directly linked to treatment.
Experimental [18] and epidemiology [19] data have
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Figure 3 Macro and microscopic images of livers from each of the groups.
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Figure 4 Expression of PCNA in the different groups.
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Page 4 of 7suggested that 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) may have potential as che-
mopreventive agents in cancer. Observational data have
also indicated that statins may have protective effects
against the development of cancer, for example, modify-
ing the risk of oesophageal adenocarcinoma in patients
with existing Barrett’s oesophagus [20]. Two studies [5,6]
published in recent years have shown that pravastatin
improved survival of patients with advanced hepatocarci-
noma. In our study, we found that pravastatin decreases
the proliferation of hepatocellular carcinoma cell lines.
This finding was then confirmed in a rat model of hepa-
tocarcinoma. Specifically, it was observed that the num-
ber of nodules of hepatocarcinoma was lower in rats
treated with pravastatin. This small number was also
associated with a relatively lower level of serum
transaminases.
The role of statins does extend beyond their lipid-low-
ering effects, as they are known to improve endothelial
function, participate in plaque stabilisation, immunomo-
dulation, antioxidant activity, and also act as anti-
inflammatory and anticancer agents. These properties
have made statins particularly attractive drugs [21]. In
this study, we observed that pravastatin decreased the
proliferation of hepatocellular carcinoma cell lines.
Immunohistochemical staining of proliferating cell
nuclear antigen (PCNA) was notably lower in pravasta-
tin group. Expression of proliferating cell nuclear anti-
gen by cells during the S and G2 phases of the cell cycle
makes the protein a good cell-proliferation marker [22].
This protein is located in the nucleus and favours the
synthesis of DNA.
Another mechanism of action of pravastatin is to
cause a decrease in the expression of Methionine Ade-
nosyltransferase (MAT). MAT is the enzyme that cata-
lyzes the synthesis of S-adenosylmethionine (AdoMet),
the main donor of methyl groups in the cell [23]. In
mammals MAT is the product of two genes, MAT1A
and MAT2A. MAT1A promoter is hypomethylated in
liver and hypermethylated in kidney and foetal rat hepa-
tocytes, indicating that this modification is tissue specific
and developmentally regulated. Southern blot analysis
with a MAT1A promoter probe demonstrated that
MAT1A expression is linked to elevated levels of chro-
matin acetylation. Early changes in MAT1A methylation
are already observed in precancerous cirrhotic livers
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Figure 5 Expression of MAT1A in the different groups.
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Page 5 of 7from rats, in which MAT1A expression is low. This
expression is reactivated in the human hepatoma cell
line HepG2 treated with 5-aza-2’-deoxycytidine or the
histone deacetylase inhibitor trichostatin, suggesting a
role for DNA hypermethylation and histone deacetyla-
tion in MAT1A silencing [23]. We observed a significant
increase in the expression of MAT1A, suggesting that
pravastatin has a protective effect against tumour
progression.
The inhibition of the products derived from mevalo-
nate may be another mechanism by which pravastatin
affects cell proliferation, differentiation and apoptosis.
Other authors [18] have reported how the statins inhibit
proliferation and induce apoptosis in oesophageal ade-
nocarcinoma cells via inhibition of Ras farnesylation and
inhibition of the extracellular signal-regulated kinases
and Akt signalling pathways. Pravastatin reduced viable
cell numbers and inhibited proliferation in a similar
dose-dependent manner. Statins induced apoptosis and
enhanced the antiproliferative effect of NS-398, a selec-
tive cyclooxygenase (COX)-2 inhibitor, while statin
treatment also increased messenger RNA (mRNA) and
protein expression of the proapoptotic proteins Bax and
Bad. Recently, it has also been observed that pravastatin
treatment effectively inhibited the production of several
pro-inflammatory/pro-angiogenic mediators involved in
inflammation and angiogenesis in vitro studies [24].
Sorafenib, a multikinase inhibitor, increases survival of
patients with advanced hepatocellular carcinoma [25]. In
one study, median overall survival was 10.7 months in the
sorafenib group and 7.9 months in the placebo group [26].
For this reason, one of our objectives was to compare the
effectiveness in vitro and in vivo of pravastatin for the
t r e a t m e n to fh e p a t o c a r c i n o m a .W eo b s e r v e dt h a tt h ec o m -
bination of pravastatin and sorafenib in vitro, considerably
decreased cell proliferation and the expression of MAT1A
in vivo. The results were confirmed in vivo. In particular,
the combination of pravastatin and sorafenib resulted in a
smaller number and size of hepatocarcinoma lesions, com-
pared to the administration of the two drugs separately. As
well as decreasing levels of PCNA and MAT1A, sorafenib
also decreased the expression of Mcl-1 messenger RNA
and protein, transcriptional targets of STAT3, as well as
sensitizing neoplastic cells to tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL)-mediated apop-
tosis [26]. In addition, sorafenib produces inhibition of the
expression of phospho-MEK, phospho-ERK, cyclin D1, Rb
and anti-apoptotic proteins Bcl-xl and Mcl-1 [27,28].
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Figure 6 Levels of AST, ALT, GGT and ALP in the different groups.
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for advanced hepatocarcinoma. The great cumulative
experience in the use of statins in clinical practice is a very
considerable advantage, facilitating the development of
clinical trials to assess any increase in survival when com-
bining these two drugs.
The most severe limitation of this study is that we
cannot know whether the response in humans would be
the same as in in vitro and in vivo models. Further, it is
not possible to assess whether or not the adverse effects
may strengthen with the use of both drugs.
To conclude, we observe that pravastatin, alone or in
combination with sorafenib has substantial antiprolifera-
tive effects in hepatocellular carcinoma cell lines in in
vitro and in vivo models of hepatocarcinoma. Studies on
humans are required to confirm these findings. Pravastatin
decreases cell proliferation in in vitro and in vivo models,
the combination of pravastatin and sorafenib being more
effective than the administration of sorafenib alone.
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